These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 24794746

  • 21. Combinatorial tuning of peptidic drug candidates: high-affinity matriptase inhibitors through incremental structure-guided optimization.
    Fittler H, Avrutina O, Glotzbach B, Empting M, Kolmar H.
    Org Biomol Chem; 2013 Mar 21; 11(11):1848-57. PubMed ID: 23361403
    [Abstract] [Full Text] [Related]

  • 22. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C.
    J Mol Biol; 2005 Mar 11; 346(5):1335-49. PubMed ID: 15713485
    [Abstract] [Full Text] [Related]

  • 23. Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin.
    Mahoney MW, Helander J, Kooner AS, Norman M, Damalanka VC, De Bona P, Kasperkiewicz P, Rut W, Poreba M, Kashipathy MM, Battaile KP, Lovell S, O'Donoghue AJ, Craik CS, Drag M, Janetka JW.
    Protein Sci; 2024 Aug 11; 33(8):e5110. PubMed ID: 39073183
    [Abstract] [Full Text] [Related]

  • 24. Potent inhibitors of human matriptase-1 based on the scaffold of sunflower trypsin inhibitor.
    Fittler H, Avrutina O, Empting M, Kolmar H.
    J Pept Sci; 2014 Jun 11; 20(6):415-20. PubMed ID: 24723440
    [Abstract] [Full Text] [Related]

  • 25. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors.
    Banke IJ, Arlt MJ, Pennington C, Kopitz C, Steinmetzer T, Schweinitz A, Gansbacher B, Quigley JP, Edwards DR, Stürzebecher J, Krüger A.
    Biol Chem; 2003 Jun 11; 384(10-11):1515-25. PubMed ID: 14669995
    [Abstract] [Full Text] [Related]

  • 26. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS, Roy KK, Saxena AK.
    J Chem Inf Model; 2011 Aug 22; 51(8):1966-85. PubMed ID: 21761917
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of bisbenzamidines as inhibitors for matriptase-2.
    Beckmann AM, Gilberg E, Gattner S, Huang TL, Vanden Eynde JJ, Mayence A, Bajorath J, Stirnberg M, Gütschow M.
    Bioorg Med Chem Lett; 2016 Aug 01; 26(15):3741-5. PubMed ID: 27287367
    [Abstract] [Full Text] [Related]

  • 28. Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.
    Dianati V, Navals P, Couture F, Desjardins R, Dame A, Kwiatkowska A, Day R, Dory YL.
    J Med Chem; 2018 Dec 27; 61(24):11250-11260. PubMed ID: 30501188
    [Abstract] [Full Text] [Related]

  • 29. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
    Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U, Fildes K, Cheung CY, Cook SM, Johnson DC, Bachovchin DA, Cook GM, Apte M, Huang M, Ranson M, Kelso MJ.
    J Med Chem; 2018 Sep 27; 61(18):8299-8320. PubMed ID: 30130401
    [Abstract] [Full Text] [Related]

  • 30. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA, Elrod K, Luong C, Rice MJ, Mackman RL, Sprengeler PA, Spencer J, Hataye J, Janc J, Link J, Litvak J, Rai R, Rice K, Sideris S, Verner E, Young W.
    J Mol Biol; 2001 Apr 13; 307(5):1451-86. PubMed ID: 11292354
    [Abstract] [Full Text] [Related]

  • 31. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
    Han Z, Harris PK, Karmakar P, Kim T, Owusu BY, Wildman SA, Klampfer L, Janetka JW.
    ChemMedChem; 2016 Mar 17; 11(6):585-99. PubMed ID: 26889658
    [Abstract] [Full Text] [Related]

  • 32. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
    Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K.
    Int J Oncol; 2005 Oct 17; 27(4):1061-70. PubMed ID: 16142324
    [Abstract] [Full Text] [Related]

  • 33. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
    Damalanka VC, Janetka JW.
    Future Med Chem; 2019 Apr 17; 11(7):743-769. PubMed ID: 30945556
    [Abstract] [Full Text] [Related]

  • 34. A reverse binding motif that contributes to specific protease inhibition by antibodies.
    Schneider EL, Lee MS, Baharuddin A, Goetz DH, Farady CJ, Ward M, Wang CI, Craik CS.
    J Mol Biol; 2012 Jan 27; 415(4):699-715. PubMed ID: 22154938
    [Abstract] [Full Text] [Related]

  • 35. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwe C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J.
    Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5712-5. PubMed ID: 19703768
    [Abstract] [Full Text] [Related]

  • 36. Species specificity of amidine-based urokinase inhibitors.
    Klinghofer V, Stewart K, McGonigal T, Smith R, Sarthy A, Nienaber V, Butler C, Dorwin S, Richardson P, Weitzberg M, Wendt M, Rockway T, Zhao X, Hulkower KI, Giranda VL.
    Biochemistry; 2001 Aug 07; 40(31):9125-31. PubMed ID: 11478879
    [Abstract] [Full Text] [Related]

  • 37. Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
    Ko CJ, Huang CC, Lin HY, Juan CP, Lan SW, Shyu HY, Wu SR, Hsiao PW, Huang HP, Shun CT, Lee MS.
    Cancer Res; 2015 Jul 15; 75(14):2949-60. PubMed ID: 26018085
    [Abstract] [Full Text] [Related]

  • 38. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
    Lin CY, Anders J, Johnson M, Dickson RB.
    J Biol Chem; 1999 Jun 25; 274(26):18237-42. PubMed ID: 10373425
    [Abstract] [Full Text] [Related]

  • 39. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL, Katz BA, Breitenbucher JG, Hui HC, Verner E, Luong C, Liu L, Sprengeler PA.
    J Med Chem; 2001 Nov 08; 44(23):3856-71. PubMed ID: 11689072
    [Abstract] [Full Text] [Related]

  • 40. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
    St-Georges C, Désilets A, Béliveau F, Ghinet M, Dion SP, Colombo É, Boudreault PL, Najmanovich RJ, Leduc R, Marsault É.
    Eur J Med Chem; 2017 Mar 31; 129():110-123. PubMed ID: 28219045
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.